Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19
Status:
Recruiting
Trial end date:
2020-12-30
Target enrollment:
Participant gender:
Summary
Phase II, one-arm, open label, multicentric study, to evaluate treatment of severe COVID-19
with sarilumab prior to entry into the intensive care unit (ICU).
Phase:
Phase 2
Details
Lead Sponsor:
Clinica Universidad de Navarra, Universidad de Navarra